This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Enzo Biochem’s Clinical Lab And Nuclea Biotechnologies Join To Market New Test For Certain High Risk Breast Cancer Patients

Stocks in this article: ENZ

Enzo Biochem Inc. (NYSE:ENZ) today announced that its Enzo Clinical Labs subsidiary and Massachusetts-based Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea’s non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer.

This blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that overexpresses the HER-2/neu protein in the tumor. Individuals with this condition tend to have a worse prognosis and a more aggressive disease that can resist certain types of chemotherapy. The test measures the portion of HER-2/neu protein that lies outside the surface of the cell and being released into the blood stream, allowing for more informed treatment decisions for a number of women who may not be responding to breast cancer treatment or may be at risk for metastatic cancer and need revised treatment plans.

“We are pleased to partner with Nuclea Biotechnologies in marketing this key assay,” said Cynthia Bowman, MD, Medical Director of Enzo Clinical Labs. “Offering the serum HER2/neu testing ties in with our expanding program of developing and making available high value esoteric testing, especially in the area of women’s health, and providing our physician clients with yet another tool with which to customize a woman’s assessment and treatment. Moreover, the use of this assay in treatment monitoring may open up our services to the Pharmaceutical market.”

“Our agreement with Enzo will serve as a catalyst for greater market reach of our serum HER-2/neu test,” said Patrick Muraca, President and CEO of Nuclea. “Enzo Labs’ long standing reputation as a leader in the delivery of high value diagnostics make them an excellent partner to increase the market’s recognition and use of this important breast cancer assay.”

Utilizing the HER-2/neu blood test while monitoring the disease’s progression will enable physicians to better adapt, combine therapies and change treatment protocols. Studies have demonstrated that use of combination chemotherapy regimens provides a statistically significant advantage for survival and tumor response in women with metastatic breast cancer.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs